These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22628056)

  • 1. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L; Dubé P; Rinke A
    Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
    Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
    Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
    Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
    Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
    Kidd M; Drozdov I; Joseph R; Pfragner R; Culler M; Modlin I
    Cancer; 2008 Aug; 113(4):690-700. PubMed ID: 18618499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.
    Doello K; Chico MA; Quiñonero F; Ortiz R; Prados J; Mesas C; Melguizo C
    Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064468
    [No Abstract]   [Full Text] [Related]  

  • 8. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
    Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
    Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
    Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
    BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
    Kulke MH; Siu LL; Tepper JE; Fisher G; Jaffe D; Haller DG; Ellis LM; Benedetti JK; Bergsland EK; Hobday TJ; Van Cutsem E; Pingpank J; Oberg K; Cohen SJ; Posner MC; Yao JC
    J Clin Oncol; 2011 Mar; 29(7):934-43. PubMed ID: 21263089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.
    Saif MW; Parikh R; Ray D; Kaye JA; Kurosky SK; Thomas K; Ramirez RA; Halfdanarson TR; Beveridge TJR; Mirakhur B; Nagar SP; Soares HP
    J Gastrointest Oncol; 2019 Aug; 10(4):674-687. PubMed ID: 31392048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
    Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
    J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
    [No Abstract]   [Full Text] [Related]  

  • 13. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.
    Capdevila J; Hernando J; Perez-Hoyos S; Roman-Gonzalez A; Grande E
    Oncologist; 2019 Dec; 24(12):e1315-e1320. PubMed ID: 31332100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
    Pusceddu S; Corti F; Prinzi N; Nichetti F; Ljevar S; Busico A; Cascella T; Leporati R; Oldani S; Pircher CC; Coppa J; Resi V; Milione M; Maccauro M; Miceli R; Tamborini E; Perrone F; Spreafico C; Niger M; Morano F; Pietrantonio F; Seregni E; Mariani L; Mazzaferro V; Di Liberti G; Fucà G; de Braud F; Vernieri C
    J Hematol Oncol; 2023 Dec; 16(1):119. PubMed ID: 38098114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.
    Di Giacinto P; Rota F; Rizza L; Campana D; Isidori A; Lania A; Lenzi A; Zuppi P; Baldelli R
    Int J Endocrinol; 2018; 2018():8126087. PubMed ID: 30057604
    [No Abstract]   [Full Text] [Related]  

  • 16. Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey.
    Hernando J; Kolarova T; Verslype C; Kaltsas G; Houchard A; Gueguen D; De Herder WW
    J Neuroendocrinol; 2023 Jun; 35(6):e13281. PubMed ID: 37290479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.
    De Divitiis C; von Arx C; Carbone R; Tatangelo F; Di Girolamo E; Romano GM; Ottaiano A; de Lutio di Castelguidone E; Iaffaioli RV; Tafuto S
    Onco Targets Ther; 2015; 8():669-75. PubMed ID: 25878507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on management of midgut neuroendocrine tumors.
    Mehrvarz Sarshekeh A; Halperin DM; Dasari A
    Int J Endocr Oncol; 2016 May; 3(2):175-189. PubMed ID: 27347369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.
    Yamaoka K; Nagashima S; Okada N; Sawayama N; Saito S; Takahashi M; Okada K; Endo K; Koizumi M; Sasanuma H; Ebihara K; Kasajima A; Fukushima N; Sata N; Ishibashi S
    Clin Case Rep; 2021 May; 9(5):e04118. PubMed ID: 34026158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the use of somatostatin analogs in oncology.
    Keskin O; Yalcin S
    Onco Targets Ther; 2013; 6():471-83. PubMed ID: 23667314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.